GI deck 4 Flashcards

1
Q

Prokinetics MOA

A

Stimulate motility of the GI tract without stimulating gastric, biliary, or pancreatic secretions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prokinetic drug

A

Metoclopramide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metoclopramide phamacodynamics

A

Metoclopramide stimulates motility in the upper GI tract.

Metoclopramide also has some actions similar to the phenothiazines and dopamine antagonists.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metoclopramide has a

A

Black Box warning due to risk of developing tardive dyskinesia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prokinetics are contraindicated in

A

gastrointestinal (GI) hemorrhage, mechanical obstruction, new surgery on the GI tract, or perforation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

prokinetics use cautiously in

A

patients with a history of depression.

Depression may occur, including suicidal ideation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

porkineitcs are used more on a

A

short term basis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Prokinetics ADR

A
Tardive dyskinesia
Depression, dizziness
Diarrhea 
Hypoglycemia in patients with diabetes
Rare: galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Prokinetics Additive ___

A

CNS depression occurs when used with other CNS depressants.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Prokineticcs increased risk of

A

EPS occurs with other drugs that have the potential for EPS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prokineitcs drugs with

A

anticholinergic effects reverse the action of metoclopramide.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prokinetics clinical use and dosing

A

GERD
Adults: 10 mg 30 minutes before meals
Diabetic gastroparesis
10 mg 30 minutes before meals and at bedtime for 2 to 8 weeks
In patients with continuous complete remission below 40 mL/minute, their therapy initiated at approximately half the recommended dosage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Prokinetics monitoring

A

Renal function
New-onset movement disorder
Depression or suicidal ideation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Prokineitcs patient education

A

Administration
Take 30 minutes before meals.
Do not double doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Prokinetics ADR

A

Drowsiness
Additive CNS depression when taken with CNS depressants (alcohol)
Reporting any involuntary movements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prokinetics lifestyle managment

A

GERD related lifestlyle changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PPI (proton pump inhibitors) are

A

Drowsiness
Additive CNS depression when taken with CNS depressants (alcohol)
Reporting any involuntary movements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PPI are used for

A

erosive gastritis, GERD, and Zollinger-Ellison syndrome and as part of a treatment of active PUD, especially duodenal ulcers caused by Helicobacter pylori

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PPI MOI

A

Reduce H+ secretion by inhibition of the H+/K+/adenosine triphosphatase (ATPase) enzyme system at the secretory surface of the parietal cell

Decrease in acid secretion lasts for up to 72 hours after each dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PPI precautions and contraindications

A

Extensively metabolized in the liver; use cautiously in patients with hepatic dysfunction and in older adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

PPI pregnancy

A

category B or C
Congenital anomalies have been reported.
Use with caution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PPI Children

A

Esomeprazole, omeprazole, and lansoprazole approved for short-term use in children as young as 1 year of age

Pantoprazole not approved in children 5 years of age and younger and rabeprazole not approved in children age less than 12 years

23
Q

PPI ADR

A

Risk for significant nutrient deficiencies: iron, vitamin B12, and calcium

24
Q

Long term PPI use increases

A

Long-term PPI use increases risk for osteoporosis and increased hip fractures
Long-term PPI therapy increases risk of Clostridium difficile, Salmonella, and Camphylobacter infections

25
Q

PPI there is an increased

A

risk of pneumonia

26
Q

PPI use questionable

A

gastric cancer risk

27
Q

PPI causes

A

kidney injury chronic kideny disease

28
Q

PPI Big picture

A

do not want them on it longer than 8 weeks. If longer than 8 weeks they should see a GI specialist

29
Q

PPI decreases effectiveness of

A

of atazanavir, indinavir, and nelfinavir

30
Q

PPI interfere with

A

absorption of drugs and depend on an acidic gastric pH to be effective

31
Q

PPI incresed monitoring of

A

international normalized ratio (INR) if taken with warfarin

32
Q

PPI with clopidogrel (plavix) has a

A

Black Box warning regarding interactions with omeprazole

33
Q

PPI clinical use and dosing for duodenal and gastric ulcers

A

PPIs are combined with antibiotics to treat H. pylori.

34
Q

PPI clinical use dosing for GERD

A

Used for 8 weeks, then patient weaned off

May need to double dose for 4 weeks and then decrease dose for another 4 weeks

35
Q

PPI may mask the symptoms of

A

gastric cancers

36
Q

PPI weaning

A

Decrease from twice/day to once/day, then every other day, with an H2RA used for symptoms, then patient weaned off.

37
Q

Six classes of laxatives

A
Stimulants
Osmotics
Bulk-producing laxatives
Lubricants
Surfactants
Hypoerosolar laxatives
Chloride chanel activators
Opioid receptor antagonists
38
Q

Laxatives Stimulants MOI

A

direct action on intestinal mucosa by stimulating the myenteric plexus

39
Q

Laxatives Osmotics MOI

A

draw water into the intestinal lumen

Bulk-producing laxatives: natural and semisynthetic polysaccharides and cellulose that mix with water in the intestine

40
Q

Laxatives Lubricants MOI

A

soften stool and lubricates intestine

41
Q

Laxatives surfactants MOI

A

reduce the surface tension of the oil–water interface on the stool and facilitate admixture of fat and water into the stool

42
Q

Laxatives hyperosmolar MOI

A

draws water into intestine

43
Q

Laxatives chloride channel activators MOI

A

activate CIC-2 chloride channels in the GI tract to produce chloride-rich secretions that soften the stool

44
Q

Laxatives opioid receport antagonits MOI

A

mu receptor antagonists

45
Q

Laxatives all are contrindicated in the

A

the presence of nausea, vomiting, or undiagnosed abdominal pain or if bowel obstruction is suspected or diagnosed

46
Q

Magnesium hydroxide contraindicated

A

renal dysfunction

47
Q

methylneltrexone may cause

A

opioid withdrawl

48
Q

laxatives ADR

A

Excessive bowel activity, cramping, flatulence, and bloating

49
Q

Laxative rapid short term use

A

Stimulants are the drugs of choice.
Osmotic laxatives also work well (magnesium hydroxide, PEG 3350).
Surfactants: docusate

50
Q

Laxative slower response

A

Bulk-forming laxatives

51
Q

Laxative for pregnancy

A

Bulk-forming laxatives are safest.

PEG (Miralax) or docusate may be used.

52
Q

Laxative rapid actving administration

A

Rapid-acting laxatives are best taken in the morning; slower-acting ones are best taken at bedtime.

53
Q

Laxative what is KEY

A

Prevention is the key.
Laxatives are temporary fixes.
Misconceptions about bowel function should be corrected.